Literature DB >> 23938945

Prostate cancer: Prostate Health Index--improving screening in men with family history.

Stacy Loeb.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23938945     DOI： 10.1038/nrurol.2013.169

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  10 in total

1.  [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study.

Authors:  Brian V Le; Christopher R Griffin; Stacy Loeb; Gustavo F Carvalhal; Donghui Kan; Nikola A Baumann; William J Catalona
Journal:  J Urol       Date:  2010-02-19       Impact factor: 7.450

2.  Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy.

Authors:  Vincenzo Scattoni; Massimo Lazzeri; Giovanni Lughezzani; Stefano De Luca; Roberto Passera; Enrico Bollito; Donato Randone; Firas Abdollah; Umberto Capitanio; Alessandro Larcher; Giuliana Lista; Giulio Maria Gadda; Vittorio Bini; Francesco Montorsi; Giorgio Guazzoni
Journal:  J Urol       Date:  2013-03-01       Impact factor: 7.450

3.  Complications after prostate biopsy: data from SEER-Medicare.

Authors:  Stacy Loeb; H Ballentine Carter; Sonja I Berndt; Winnie Ricker; Edward M Schaeffer
Journal:  J Urol       Date:  2011-09-23       Impact factor: 7.450

4.  Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.

Authors:  Giorgio Guazzoni; Luciano Nava; Massimo Lazzeri; Vincenzo Scattoni; Giovanni Lughezzani; Carmen Maccagnano; Fernanda Dorigatti; Ferruccio Ceriotti; Marina Pontillo; Vittorio Bini; Massimo Freschi; Francesco Montorsi; Patrizio Rigatti
Journal:  Eur Urol       Date:  2011-04-05       Impact factor: 20.096

5.  A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range.

Authors:  William J Catalona; Alan W Partin; Martin G Sanda; John T Wei; George G Klee; Chris H Bangma; Kevin M Slawin; Leonard S Marks; Stacy Loeb; Dennis L Broyles; Sanghyuk S Shin; Amabelle B Cruz; Daniel W Chan; Lori J Sokoll; William L Roberts; Ron H N van Schaik; Isaac A Mizrahi
Journal:  J Urol       Date:  2011-03-17       Impact factor: 7.450

6.  Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project.

Authors:  Massimo Lazzeri; Alexander Haese; Alberto Abrate; Alexandre de la Taille; Joan Palou Redorta; Thomas McNicholas; Giovanni Lughezzani; Giuliana Lista; Alessandro Larcher; Vittorio Bini; Andrea Cestari; Nicolòmaria Buffi; Markus Graefen; Olivier Bosset; Philippe Le Corvoisier; Alberto Breda; Pablo de la Torre; Linda Fowler; Jacques Roux; Giorgio Guazzoni
Journal:  BJU Int       Date:  2013-08       Impact factor: 5.588

7.  Prostate-cancer mortality at 11 years of follow-up.

Authors:  Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Stefano Ciatto; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Hans Lilja; Marco Zappa; Louis J Denis; Franz Recker; Alvaro Páez; Liisa Määttänen; Chris H Bangma; Gunnar Aus; Sigrid Carlsson; Arnauld Villers; Xavier Rebillard; Theodorus van der Kwast; Paula M Kujala; Bert G Blijenberg; Ulf-Hakan Stenman; Andreas Huber; Kimmo Taari; Matti Hakama; Sue M Moss; Harry J de Koning; Anssi Auvinen
Journal:  N Engl J Med       Date:  2012-03-15       Impact factor: 91.245

8.  Development and internal validation of a Prostate Health Index based nomogram for predicting prostate cancer at extended biopsy.

Authors:  Giovanni Lughezzani; Massimo Lazzeri; Alessandro Larcher; Giuliana Lista; Vincenzo Scattoni; Andrea Cestari; Nicoló Maria Buffi; Vittorio Bini; Giorgio Guazzoni
Journal:  J Urol       Date:  2012-08-15       Impact factor: 7.450

9.  Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study.

Authors:  Massimo Lazzeri; Alexander Haese; Alexandre de la Taille; Joan Palou Redorta; Thomas McNicholas; Giovanni Lughezzani; Vincenzo Scattoni; Vittorio Bini; Massimo Freschi; Amy Sussman; Bijan Ghaleh; Philippe Le Corvoisier; Josep Alberola Bou; Salvador Esquena Fernández; Markus Graefen; Giorgio Guazzoni
Journal:  Eur Urol       Date:  2013-01-24       Impact factor: 20.096

10.  Application of the 2013 American Urological Association early detection of prostate cancer guideline: who will we miss?

Authors:  Gregory B Auffenberg; Joshua J Meeks
Journal:  World J Urol       Date:  2014-06-20       Impact factor: 4.226
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.